K Polyak

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi The microenvironment in breast cancer progression: biology and implications for treatment
    Andrew E Place
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, D740C, Boston, MA 02215, USA
    Breast Cancer Res 13:227. 2011
  2. ncbi Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9
    Dengfeng Cao
    Departments of Pathology and Immunology, Washington University, St Louis, MO, USA
    Breast Cancer Res 10:R91. 2008
  3. ncbi EMSY links breast cancer gene 2 to the 'Royal Family'
    Jun Yao
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:201-3. 2004
  4. ncbi An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
    Fariba Behbod
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Breast Cancer Res 11:R66. 2009
  5. ncbi Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:265-73. 2009
  6. ncbi Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Mol Cancer Res 2:489-94. 2004
  7. ncbi Co-evolution of tumor cells and their microenvironment
    Kornelia Polyak
    Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Trends Genet 25:30-8. 2009
  8. ncbi Pregnancy and breast cancer: the other side of the coin
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 9:151-3. 2006
  9. ncbi Do myoepithelial cells hold the key for breast tumor progression?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street D740C, Boston, Massachusetts 02115, USA
    J Mammary Gland Biol Neoplasia 10:231-47. 2005
  10. ncbi The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School and Brigham and Women s Hospital, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 10:352-4. 2006

Research Grants

  1. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2010
  2. HIN-1,A Novel Putative Breast Tumor Suppressor Gene
    Kornelia Polyak; Fiscal Year: 2006
  3. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2009

Detail Information

Publications82

  1. ncbi The microenvironment in breast cancer progression: biology and implications for treatment
    Andrew E Place
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, D740C, Boston, MA 02215, USA
    Breast Cancer Res 13:227. 2011
    ..There is increasing interest in translating our current understanding of the tumor microenvironment to the development of novel therapies...
  2. ncbi Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9
    Dengfeng Cao
    Departments of Pathology and Immunology, Washington University, St Louis, MO, USA
    Breast Cancer Res 10:R91. 2008
    ..Global gene expression profiling of LCIS has not been performed...
  3. ncbi EMSY links breast cancer gene 2 to the 'Royal Family'
    Jun Yao
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:201-3. 2004
    ..Furthermore, EMSY's binding to members of the 'Royal Family' of chromatin remodeling proteins may lead to a better understanding of the physiological function of BRCA2 and its role in chromatin remodeling...
  4. ncbi An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
    Fariba Behbod
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Breast Cancer Res 11:R66. 2009
    ..The resulting models, which mimicked some of the diversity of human noninvasive breast cancers in vivo, were used to show whether subtypes of human DCIS might contain distinct subpopulations of tumor-initiating cells...
  5. ncbi Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:265-73. 2009
    ....
  6. ncbi Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Mol Cancer Res 2:489-94. 2004
    ..Thus, silencing of HIN-1 expression and methylation of its promoter occurs in multiple human cancer types, suggesting that elimination of HIN-1 function may contribute to several forms of epithelial tumorigenesis...
  7. ncbi Co-evolution of tumor cells and their microenvironment
    Kornelia Polyak
    Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Trends Genet 25:30-8. 2009
    ..A thorough understanding of the co-evolution of these two cellular compartments will require carefully executed molecular studies combined with mathematical modeling...
  8. ncbi Pregnancy and breast cancer: the other side of the coin
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 9:151-3. 2006
    ....
  9. ncbi Do myoepithelial cells hold the key for breast tumor progression?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street D740C, Boston, Massachusetts 02115, USA
    J Mammary Gland Biol Neoplasia 10:231-47. 2005
    ..Better understanding of myoepithelial cell function and their role in tumor progression may lead to their exploitation for cancer therapeutic and preventative measures...
  10. ncbi The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School and Brigham and Women s Hospital, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 10:352-4. 2006
    ..However, a recent study links germline mutations in p27Kip1 to multiple endocrine neoplasia syndrome in rats and humans, thus establishing p27Kip1 as a bona fide tumor suppressor gene...
  11. ncbi Breast cancer stem cells: a case of mistaken identity?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Stem Cell Rev 3:107-9. 2007
  12. ncbi Breast cancer: origins and evolution
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:3155-63. 2007
    ..Comprehensive unbiased studies of tumors and patient populations have significantly advanced our molecular understanding of breast cancer, but translating these findings into clinical practice remains a challenge...
  13. ncbi Is breast tumor progression really linear?
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 14:339-41. 2008
  14. ncbi Breast cancer gene discovery
    Kornelia Polyak
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Expert Rev Mol Med 4:1-18. 2002
    ..Recently developed genomic technologies and the completion of the human genome sequence provide us with powerful tools to identify novel candidate breast cancer genes that could play an important role in breast tumourigenesis...
  15. ncbi Molecular alterations in ductal carcinoma in situ of the breast
    Kornelia Polyak
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:92-6. 2002
    ....
  16. ncbi Heterogeneity in breast cancer
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 121:3786-8. 2011
    ..The articles in this Review series discuss recent advances in our understanding of breast tumor heterogeneity, therapies tailored based on this knowledge, and future ways of assessing and treating heterogeneous tumors...
  17. ncbi On the birth of breast cancer
    K Polyak
    Dana Farber Cancer Institute and Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Biochim Biophys Acta 1552:1-13. 2001
    ....
  18. ncbi Molecular markers for the diagnosis and management of ductal carcinoma in situ
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St D740C, Boston, MA 02115, USA
    J Natl Cancer Inst Monogr 2010:210-3. 2010
    ..Comprehensive molecular studies analyzing large cohorts of DCIS with long-term clinical follow-up are necessary to resolve the many remaining questions...
  19. ncbi Is p53 a breast cancer gene?
    Kornelia Polyak
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 1:37-8. 2002
  20. ncbi The role of the microenvironment in mammary gland development and cancer
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cold Spring Harb Perspect Biol 2:a003244. 2010
    ..In this article, we overview the importance of cellular interactions and microenvironmental signals in mammary gland development and cancer...
  21. ncbi HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells
    I E Krop
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:9796-801. 2001
    ..Reintroduction of HIN-1 into breast cancer cells inhibits cell growth. These results indicate that HIN-1 is a candidate tumor suppressor gene that is inactivated at high frequency in the earliest stages of breast tumorogenesis...
  22. ncbi A SAGE (serial analysis of gene expression) view of breast tumor progression
    D A Porter
    Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 61:5697-702. 2001
    ....
  23. ncbi Molecular characterization of the tumor microenvironment in breast cancer
    Minna Allinen
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 6:17-32. 2004
    ..Thus, chemokines may play a role in breast tumorigenesis by acting as paracrine factors...
  24. ncbi Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:2024-7. 2003
    ..006), suggesting that HIN-1 methylation patterns are associated with specific breast cancer subtypes...
  25. ncbi Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:3372-7. 2009
    ....
  26. ncbi DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma
    Mary Jo Fackler
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 401 N Broadway, Baltimore, MD 21231 2410, USA
    Int J Cancer 107:970-5. 2003
    ..01). These results suggest that these 2 types of tumors share many common methylation patterns and some molecular differences. Additional studies might lend further understanding into the etiology and clinical behavior of this tumor type...
  27. ncbi Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung
    Jyoti Mehrotra
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 10:3104-9. 2004
    ....
  28. ncbi Epigenetic patterns of embryonic and adult stem cells
    Noga Bloushtain-Qimron
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cell Cycle 8:809-17. 2009
    ....
  29. ncbi Molecular definition of breast tumor heterogeneity
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 11:259-73. 2007
    ..Our data suggest prognostic relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations...
  30. ncbi HIN-1, an inhibitor of cell growth, invasion, and AKT activation
    Ian Krop
    Department of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:9659-69. 2005
    ..Taken together, these studies provide further evidence that HIN-1 possesses tumor suppressor functions, and that these activities may be mediated through the AKT signaling pathway...
  31. ncbi Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues
    Dale Porter
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mech Dev 114:201-4. 2002
    ..The expression of HIN-1 is restricted to terminally differentiated airway epithelial cells in vivo and in vitro implicating HIN-1 in the acquisition or maintenance of terminally differentiated epithelial phenotype...
  32. ncbi Psoriasin expression in mammary epithelial cells in vitro and in vivo
    Charlotta Enerback
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:43-7. 2002
    ..All of these conditions are characteristic of high-grade DCIS and psoriatic skin lesions; therefore, the same mechanisms may be responsible for increased expression of psoriasin in vitro and in vivo...
  33. ncbi Microenvironmental regulation of cancer development
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Curr Opin Genet Dev 18:27-34. 2008
    ..Better understanding the molecular mechanisms by which stromal cells exert these effects may open up new venues for cancer therapeutic and preventative interventions...
  34. ncbi Cancer target discovery using SAGE
    Dale Porter
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Expert Opin Ther Targets 7:759-69. 2003
    ..Comprehensive analyses of expression profiles using SAGE will yield many new diagnostic and prognostic markers as well as therapeutic targets in cancer...
  35. ncbi Gene discovery using the serial analysis of gene expression technique: implications for cancer research
    K Polyak
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:2948-58. 2001
    ....
  36. ncbi Cell type-specific DNA methylation patterns in the human breast
    Noga Bloushtain-Qimron
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:14076-81. 2008
    ..These data suggest that epigenetically controlled transcription factors play a key role in regulating mammary epithelial cell phenotypes and imply similarities among epigenetic programs that define progenitor cell characteristics...
  37. ncbi Regulation of in situ to invasive breast carcinoma transition
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 13:394-406. 2008
    ....
  38. ncbi Distinct epigenetic changes in the stromal cells of breast cancers
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 37:899-905. 2005
    ....
  39. ncbi Molecular characterisation of the tumour microenvironment in breast cancer
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 44:2760-5. 2008
    ....
  40. ncbi The origins and implications of intratumor heterogeneity
    Franziska Michor
    Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:1361-4. 2010
    ..This work helps elucidate the implications of molecular heterogeneity for the evolution of neoplasia...
  41. ncbi Cyclooxygenase-2 expression during immortalization and breast cancer progression
    Xiangshan Zhao
    Division of Cancer Biology, Department of Medicine, Evanston Northwestern Healthcare Research Institute and Feinberg School of Medicine, Evanston, IL, USA
    Cancer Res 68:467-75. 2008
    ....
  42. ncbi The epithelial-mesenchymal transition generates cells with properties of stem cells
    Sendurai A Mani
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Cell 133:704-15. 2008
    ..These findings illustrate a direct link between the EMT and the gain of epithelial stem cell properties...
  43. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  44. ncbi PIK3CA mutations in in situ and invasive breast carcinomas
    Alexander Miron
    Department of Cancer Biology, and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 70:5674-8. 2010
    ....
  45. ncbi Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression
    Jun Yao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 66:4065-78. 2006
    ..These results show the power of combined array CGH and SAGE analysis for the identification of candidate amplicon targets and identify H2AFJ and EPS8 as novel putative oncogenes in breast cancer...
  46. ncbi Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression
    Celina G Kleer
    Department of Pathology, University of Michigan Cancer Center, Ann Arbor, Michigan, USA
    Clin Cancer Res 14:5357-67. 2008
    ..To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression...
  47. ncbi SAGE and related approaches for cancer target identification
    Dale Porter
    Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Drug Discov Today 11:110-8. 2006
    ....
  48. ncbi Identifying tumor origin using a gene expression-based classification map
    Phillip Buckhaults
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 63:4144-9. 2003
    ..This expression map analysis may provide a reliable and practical approach to determine tumor type in cases of metastatic carcinoma of clinically unknown origin...
  49. ncbi Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
    ..We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting...
  50. ncbi Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype
    So Yeon Park
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 120:636-44. 2010
    ..Our findings highlight the importance of genetic diversity in intratumor heterogeneity and the value of analyzing tumors as distinct populations of cancer cells to more effectively plan treatments...
  51. ncbi A neural survival factor is a candidate oncogene in breast cancer
    Dale Porter
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:10931-6. 2003
    ..Based on these data we hypothesize that DCD may play a role in tumorigenesis by means of enhancing cell growth and survival in a subset of breast carcinomas...
  52. ncbi Breast tumor heterogeneity: cancer stem cells or clonal evolution?
    Lauren L Campbell
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cell Cycle 6:2332-8. 2007
    ..An understanding of this process will allow the development of more effective ways to treat and prevent breast cancer...
  53. ncbi Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase
    Qing Zhang
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 16:413-24. 2009
    ..EglN2 depletion also impairs the fitness of lung, brain, and hematopoietic cancer lines. These findings support the exploration of EglN2 inhibitors as therapeutics for estrogen-dependent breast cancer and other malignancies...
  54. ncbi Roots and stems: stem cells in cancer
    Kornelia Polyak
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Med 12:296-300. 2006
    ....
  55. ncbi Cellular and molecular targets of estrogen in normal human breast tissue
    Pankaj Seth
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 62:4540-4. 2002
    ..These results demonstrate that normal and cancerous estrogen receptor-positive cells are distinct at the molecular level and suggest that lipocalin 2 is a new therapeutic target for breast cancer prevention and treatment...
  56. ncbi A putative role for psoriasin in breast tumor progression
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:11326-34. 2005
    ....
  57. ncbi Integrative genomic approaches identify IKBKE as a breast cancer oncogene
    Jesse S Boehm
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cell 129:1065-79. 2007
    ..These observations suggest a mechanism for NF-kappaB activation in breast cancer, implicate the NF-kappaB pathway as a downstream mediator of PI3K, and provide a framework for integrated genomic approaches in oncogene discovery...
  58. ncbi No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas
    Wen Qiu
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Nat Genet 40:650-5. 2008
    ..Our data show conclusively that LOH and copy number alterations are extremely rare in CAFs and cannot be the basis of the carcinoma-promoting phenotypes of breast and ovarian CAFs...
  59. ncbi Cancer chromosomes in crisis
    Ronald A Depinho
    Nat Genet 36:932-4. 2004
    ....
  60. ncbi PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling
    Y Shrestha
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Oncogene 31:3397-408. 2012
    ....
  61. ncbi Detection of psoriasin/S100A7 in the sera of patients with psoriasis
    K S Anderson
    Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Dermatol 160:325-32. 2009
    ..Psoriatic keratinocytes express high levels of psoriasin (S100A7), a small calcium-binding protein...
  62. ncbi Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer
    P Seth
    Departent of Adult Oncology, Dana Farher Cancer Institute, Boston, Massachasetts 02115, USA
    Cancer Res 60:6859-63. 2000
    ..The large number of environmental mutagens and carcinogens activated by sulfotransferases and the high frequency of the SULT1A1*1 allele in human populations warrants additional studies to address the role of SULT genes in human cancer...
  63. ncbi Molecular markers in ductal carcinoma in situ of the breast
    Dale Porter
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Res 1:362-75. 2003
    ..The majority of invasive cancer specific SAGE tags correspond to novel genes. The genes we identified may define biologically and clinically meaningful subgroups of DCIS with a high risk of progression to invasive disease...
  64. ncbi S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation
    Vikram Paruchuri
    Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 3:e1741. 2008
    ..This is a novel report on the role of S100A7 in EGF-induced signaling in breast cancer cells and in osteoclast formation...
  65. ncbi Cancer stem cells: a model in the making
    Lauren L Campbell Marotta
    Department of Medical Oncology, Dana Farber Cancer Institute, Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Genet Dev 19:44-50. 2009
    ..Looking into the many questions that remain about the cancer stem cells model might lead to more effective cancer prevention, diagnosis, and treatment...
  66. ncbi The cancer stem cell hypothesis: in search of definitions, markers, and relevance
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Lab Invest 88:459-63. 2008
    ..Rigorous study design and critical data interpretation have to be employed to test the scientific and clinical relevance of the cancer stem cell hypothesis and its relationship to the clonal evolution model...
  67. ncbi Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)
    Pankaj Seth
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:836-43. 2002
    ..These data indicate that EIT-6 may play a role in estrogen induced cell growth...
  68. ncbi Methylation-specific digital karyotyping
    Min Hu
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Nat Protoc 1:1621-36. 2006
    ..The number of tags in an MSDK library reflects the methylation status of the mapping enzyme sites. Generation of MSDK libraries can be completed in 7-10 days, whereas sequencing and data analysis requires an additional 3-4 weeks...
  69. ncbi Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies
    Eric L Snyder
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Lab Invest 89:857-66. 2009
    ....
  70. ncbi Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women
    Jyoti Mehrotra
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 10:2052-7. 2004
    ....
  71. ncbi Contribution of bone marrow-derived endothelial cells to human tumor vasculature
    Brock A Peters
    The Sidney Kimmel Comprehensive Cancer Center and Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Med 11:261-2. 2005
    ..These results illustrate substantial differences between human tumors and many mouse models with respect to angiogenesis and have important implications for the translation of experimental antiangiogenic therapies to the clinic...
  72. ncbi Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants
    Hanna Carlsson
    Department of Clinical Genetics, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biol Ther 4:998-1005. 2005
    ....
  73. ncbi Breast-cancer stromal cells with TP53 mutations
    Ian G Campbell
    N Engl J Med 358:1634-5; author reply 1636. 2008
  74. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  75. ncbi Ductal carcinoma in situ of the breast
    Harold J Burstein
    Division of Medical Oncology and the Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1430-41. 2004
  76. ncbi Tumor heterogeneity: causes and consequences
    Andriy Marusyk
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Biochim Biophys Acta 1805:105-17. 2010
    ..Furthermore, we discuss potential biological and clinical implications of intra-tumor clonal heterogeneity...
  77. ncbi Serial analysis of gene expression
    Min Hu
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, D740C, Boston, Massachusetts 02115, USA
    Nat Protoc 1:1743-60. 2006
    ..The generation of such libraries can be completed in 7-10 d, whereas sequencing and data analysis require an additional 2-3 wk...
  78. ncbi Serial analysis of gene expression (SAGE): experimental method and data analysis
    Seth Blackshaw
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Curr Protoc Hum Genet . 2007
    ..Software tools have also been specifically adapted for SAGE tags to allow cluster analysis of both public and user-generated data...
  79. ncbi An anatomy of normal and malignant gene expression
    Kathy Boon
    Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 99:11287-92. 2002
    ..We report here an easily accessible view of nearly any gene's expression in a wide variety of malignant and normal tissues...
  80. ncbi Moving AHEAD with an international human epigenome project
    Peter A Jones
    Nature 454:711-5. 2008
  81. ncbi The hairy powers of oncogenes: from biological function to cancer therapy
    Kornelia Polyak
    Dana-Farber Cancer Institute, Harvard Medical School; Boston, Massachusetts USA
    Cancer Biol Ther 2:592-4. 2003
  82. ncbi Serial analysis of gene expression (SAGE): experimental method and data analysis
    Seth Blackshaw
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Curr Protoc Mol Biol . 2007
    ..Software tools have also been specifically adapted for SAGE tags to allow cluster analysis of both public and user-generated data...

Research Grants11

  1. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2010
    ....
  2. HIN-1,A Novel Putative Breast Tumor Suppressor Gene
    Kornelia Polyak; Fiscal Year: 2006
    ..abstract_text> ..
  3. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2009
    ....